NCT01212913 - Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

INSULIN GLARGINE

Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily

DRUG

INSULIN GLULISINE

Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily

DRUG

Insulin aspart

Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily

Trial Locations (1)

Administrative Office, Seoul